CALGARY, March 20, 2018 /PRNewswire/ - Kent Imaging Inc. announced today a strategic relationship with Allergan Canada toadvance tissue assessment in Canada.
This opportunity adds the Kent device to Allegan Canada's Medical Aesthetics division with another solution for breast augmentation surgery along with AlloDerm®,
The Kent device is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent's multispectral imaging technology displays two-dimensional colour-coded images providing critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes in breast, reconstructive, and various other plastic surgery applications.
"With the Kent device, we can quantify oxygenation which is the best biomarker for tissue health and predictor of tissue viability in creating flaps with surgically reconstructed patients," said Carmen Enciu, Medical Director and Head of the Canadian Chief Medical Office. "This opportunity further reinforces Allergan Canada's commitment to patients in need of treatment by finding innovative technologies that improve outcomes."
"We are very excited about this strategic partnership", said Pierre Lemire, CEO of Kent Imaging. "Working with Allergan Canada, we can help physicians determine the most effective treatment plans which provides them a means of reducing recovery times and patient discomfort, as well as optimizing patient outcomes."
Features of Kent's Tissue Oxygenation Assessment device:
Kent is now available for sale in both the United States and Canada.
About Kent Imaging Inc.
Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about our company visit us at www.kentimaging.com.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com
SOURCE Kent Imaging
Subscribe to our Free Newsletters!